Name: CERVOMED INC (CRVO) Stock
Brand: CERVOMED INC
Rating: 5.5 (3 reviews)

CRVO Latest News, Press Relases and Analysis

All

Press Releases

2 days ago - By: CervoMed Inc.

CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference

16 days ago - By: CervoMed Inc.

CervoMed Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

19 days ago - By: Zacks Investment Research - Mentions: CUE

CervoMed Inc. (CRVO) Reports Q3 Loss, Misses Revenue Estimates

21 days ago - By: Benzinga - Mentions: VNDA QLYS DCBO AAPG

This Docebo Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Wednesday

3 months ago - By: Stocktwits - Mentions: VTI IWC

CervoMed Gets $11 Price Target From HC Wainwright, Analyst Says Regulatory Outlook For Experimental Dementia Drug Should Be Clear Soon

21 days ago - By: Benzinga - Mentions: VNDA ADM SO TREX ...

This Trex Company Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday

a month ago - By: CervoMed Inc.

CervoMed to Present at the Emerging Growth Conference

2 months ago - By: CervoMed Inc.

CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies

2 months ago - By: CervoMed Inc.

CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

2 months ago - By: CervoMed Inc.

CervoMed Highlights Neflamapimod's Potential Benefits in Session on Dementia with Lewy Bodies at the 150th Annual American Neurology Association Conference

3 months ago - By: CervoMed Inc.

CervoMed to Participate in Upcoming Investor Conferences

4 months ago - By: CervoMed Inc.

CervoMed Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

4 months ago - By: Zacks Investment Research - Mentions: SGMO

Sangamo Therapeutics (SGMO) Reports Q2 Loss, Lags Revenue Estimates

4 months ago - By: Zacks Investment Research - Mentions: NAGE

Niagen Bioscience (NAGE) Q2 Earnings and Revenues Surpass Estimates

4 months ago - By: CervoMed Inc.

CervoMed to Participate in the Canaccord Genuity 45th Annual Growth Conference

4 months ago - By: Stocktwits - Mentions: IWMW VTWG

CervoMed Dementia Drug Slows Disease Progression In Study: Retail Loads Up On The Stock

4 months ago - By: CervoMed Inc.

CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod’s Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration

4 months ago - By: CervoMed Inc.

CervoMed to Present New Data from Phase 2b RewinD-LB Study at AAIC 2025 and Host Conference Call on July 28, 2025

5 months ago - By: Yahoo Finance

CervoMed Strengthens Leadership with Technical Operations Hire to Advance Neflamapimod Toward Phase 3

5 months ago - By: CervoMed Inc.

CervoMed Announces Late-Breaking Presentations at Alzheimer’s Association® International Congress 2025

7 months ago - By: Zacks Investment Research - Mentions: RPTX

CervoMed Inc. (CRVO) Reports Q1 Loss, Tops Revenue Estimates

7 months ago - By: CervoMed Inc.

CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates

8 months ago - By: CervoMed Inc.

Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Presentation at AD/PD™ 2025

8 months ago - By: CervoMed Inc.

CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurologic Disorders (AP/PD™)

CERVOMED INC (CRVO) Stock News

CRVO Latest News, Press Relases and Analysis